{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:40:13Z","timestamp":1727743213757},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00393-024-01515-w","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T16:01:27Z","timestamp":1717689687000},"page":"528-535","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Verlauf der COVID-19-Pandemie bei p\u00e4diatrisch-rheumatologischen Patienten in Deutschland \u00fcber die ersten 3\u00a0Jahre (2020 bis 2022)","Course of the COVID-19 pandemic in pediatric rheumatological patients in Germany during the first 3 years (2020\u20132022)"],"prefix":"10.1007","volume":"83","author":[{"given":"Ariane","family":"Klein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Iko","family":"Huppertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Horneff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"1515_CR1","unstructured":"Robert-Koch-Institut: VOC_VOI_Tabelle.xlsx; live.com"},{"issue":"7821","key":"1515_CR2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson\u00a0EJ, Walker\u00a0AJ, Bhaskaran\u00a0K et\u00a0al (2020) Factors associated with COVID-19-related death using openSAFELY. Nature 584(7821):430\u2013436","journal-title":"Nature"},{"issue":"5","key":"1515_CR3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/acr.24831","volume":"74","author":"Y Wang","year":"2022","unstructured":"Wang\u00a0Y, D\u2019Silva\u00a0KM, Jorge\u00a0AM et\u00a0al (2022) Increased Risk of COVID-19 in Patients With Rheumatoid Arthritis: A\u00a0General Population-Based Cohort Study. Arthritis Care Res 74(5):741\u2013747","journal-title":"Arthritis Care Res"},{"issue":"12","key":"1515_CR4","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/art.41800","volume":"73","author":"BR England","year":"2021","unstructured":"England\u00a0BR, Roul\u00a0P, Yang\u00a0Y et\u00a0al (2021) Risk of COVID-19 in rheumatoid arthritis: a\u00a0national veterans affairs matched cohort study in at-risk individuals. Arthritis Rheumatol 73(12):2179\u20132188","journal-title":"Arthritis Rheumatol"},{"key":"1515_CR5","doi-asserted-by":"crossref","unstructured":"Hasseli R, Mueller-Ladner U, Hoyer BF et\u00a0al (2021) Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open 7(1)","DOI":"10.1136\/rmdopen-2020-001464"},{"issue":"7","key":"1515_CR6","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","volume":"80","author":"A Strangfeld","year":"2021","unstructured":"Strangfeld\u00a0A, Sch\u00e4fer\u00a0M, Gianfrancesco\u00a0MA et\u00a0al (2021) COVID-19 global rheumatology alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 80(7):930\u2013942","journal-title":"Ann Rheum Dis"},{"key":"1515_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41525-021-00220-w","volume":"6","author":"A Schmidt","year":"2021","unstructured":"Schmidt\u00a0A, Peters\u00a0S, Knaus\u00a0A et\u00a0al (2021) Tbk1 and TNFRSF13B mutations and an autoinflammatory disease in a\u00a0child with lethal COVID-19. NPJ Genom Med 6:55","journal-title":"NPJ Genom Med"},{"issue":"5","key":"1515_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1136\/ard.2010.128637","volume":"70","author":"K Au","year":"2011","unstructured":"Au\u00a0K, Reed\u00a0G, Curtis\u00a0JR, Kremer\u00a0JM, Greenberg\u00a0JD, Strand\u00a0V et\u00a0al (2011) High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 70(5):785\u2013791","journal-title":"Ann Rheum Dis"},{"key":"1515_CR9","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1002\/art.34458","volume":"64","author":"T Beukelman","year":"2012","unstructured":"Beukelman\u00a0T, Xie\u00a0F, Chen\u00a0L, Baddley\u00a0JW, Delzell\u00a0E, Grijalva\u00a0CG et\u00a0al (2012) Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64:2773\u20132780","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1515_CR10","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/acr.22961","volume":"69","author":"I Becker","year":"2017","unstructured":"Becker\u00a0I, Horneff\u00a0G (2017) Risk of serious infection in juvenile idiopathic arthritis patients associated with tumor necrosis factor inhibitors and disease activity in the German biologics in pediatric rheumatology registry. Arthritis Care Res 69(4):552\u2013560","journal-title":"Arthritis Care Res"},{"issue":"7","key":"1515_CR11","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","volume":"79","author":"M Gianfrancesco","year":"2020","unstructured":"Gianfrancesco\u00a0M, Hyrich\u00a0KL, Al-Adely\u00a0S et\u00a0al (2020) COVID-19 global rheumatology alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 79(7):859\u2013866","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1515_CR12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","volume":"80","author":"JA Sparks","year":"2021","unstructured":"Sparks\u00a0JA, Wallace\u00a0ZS, Seet\u00a0AM et\u00a0al (2021) COVID-19 global rheumatology alliance. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry. Ann Rheum Dis 80(9):1137\u20131146","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1515_CR13","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/annrheumdis-2022-222241","volume":"81","author":"L Kearsley-Fleet","year":"2022","unstructured":"Kearsley-Fleet\u00a0L, Chang\u00a0ML, Lawson-Tovey\u00a0S et\u00a0al (2022) Outcomes of SARS-CoV\u20112 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases. Ann Rheum Dis 81(7):998\u20131005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1515_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12969-021-00568-4","volume":"19","author":"DS Villacis-Nunez","year":"2021","unstructured":"Villacis-Nunez\u00a0DS, Rostad\u00a0CA, Rouster-Stevens\u00a0K, Khosroshahi\u00a0A, Chandrakasan\u00a0S, Prahalad\u00a0S (2021) Outcomes of COVID-19 in a\u00a0cohort of pediatric patients with rheumatic diseases. Pediatr Rheumatol Online\u00a0J 19(1):94","journal-title":"Pediatr Rheumatol Online J"},{"issue":"6","key":"1515_CR15","first-page":"1271","volume":"38","author":"M Yildiz","year":"2020","unstructured":"Yildiz\u00a0M, Haslak\u00a0F, Adrovic\u00a0A, Sahin\u00a0S, Barut\u00a0K, Kasapcopur\u00a0O (2020) The frequency and clinical course of COVID-19 infection in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 38(6):1271\u20131272","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"1515_CR16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3390\/v15051205","volume":"15","author":"H Wakiguchi","year":"2023","unstructured":"Wakiguchi\u00a0H, Kaneko\u00a0U, Sato\u00a0S, Imagawa\u00a0T, Narazaki\u00a0H, Miyamae\u00a0T (2023) Clinical Features of COVID-19 in Pediatric Rheumatic Diseases: 2020\u20132022 Survey of the Pediatric Rheumatology Association of Japan. Viruses 15(5):1205","journal-title":"Viruses"},{"issue":"1","key":"1515_CR17","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13075-020-02326-5","volume":"22","author":"G Armaroli","year":"2020","unstructured":"Armaroli\u00a0G, Klein\u00a0A, Ganser\u00a0G, Ruehlmann\u00a0MJ, Dressler\u00a0F, Hospach\u00a0A, Minden\u00a0K, Trauzeddel\u00a0R, Foeldvari\u00a0I, Kuemmerle-Deschner\u00a0J, Weller-Heinemann\u00a0F, Urban\u00a0A, Horneff\u00a0G (2020) Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry. Arthritis Res Ther 22(1):258","journal-title":"Arthritis Res Ther"},{"key":"1515_CR18","volume-title":"Coronavirus Disease 2019 (COVID-19): situation report","author":"W.H. Organization","year":"2020","unstructured":"W.H. Organization (2020) Coronavirus Disease 2019 (COVID-19): situation report"},{"issue":"20","key":"1515_CR19","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1001\/jama.2020.6775","volume":"323","author":"S Richardson","year":"2020","unstructured":"Richardson\u00a0S, Hirsch\u00a0JS, Narasimhan\u00a0M et\u00a0al (2020) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 323(20):1989\u20132104","journal-title":"JAMA"},{"issue":"3","key":"1515_CR20","doi-asserted-by":"publisher","first-page":"e001896","DOI":"10.1136\/rmdopen-2021-001896","volume":"7","author":"AC Regierer","year":"2021","unstructured":"Regierer\u00a0AC, Hasseli\u00a0R, Sch\u00e4fer\u00a0M et\u00a0al (2021) TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV\u20112 infection in patients with RMD. RMD Open 7(3):e1896. https:\/\/doi.org\/10.1136\/rmdopen-2021-001896","journal-title":"RMD Open"},{"key":"1515_CR21","unstructured":"https:\/\/experience.arcgis.com\/experience\/478220a4c454480e823b17327b2bf1d4"},{"key":"1515_CR22","unstructured":"https:\/\/dgpi.de\/covid-19-survey-update"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01515-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01515-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01515-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:02:42Z","timestamp":1727740962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01515-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1515"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01515-w","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2024,6,6]]},"assertion":[{"value":"15 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Horneff: Vortragst\u00e4tigkeit f\u00fcr AbbVie, Boehringer Ingelheim, Celgene, Chugai, GSK, Janssen, MSD, Novartis, Pfizer, Roche, Sobi. A.\u00a0Klein und H.-I.\u00a0Huppertz geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}